Phenylbutazone (Butapyrin and Butazolidin) has been rather widely employed recently in the treatment of arthritic and rheumatoid conditions. Although reports in the American literature are, at present, scanty, numerous undesirable effects have been reported following administration of this drug. Occurring in 23 to 44% of patients reported on, these untoward reactions have included dermatitides, edema, vertigo, anemia, and gastrointestinal complaints.1 Several observers have noted the appearance or reactivation of duodenal ulceration following the administration of phenylbutazone, confirmed in many instances by roentgen study. It has been observed that all these manifestations cleared on discontinuance of use of the drug. We have found no previous reports of peptic ulcer perforation occurring during or immediately following the administration of phenylbutazone and believe, therefore, that the following cases should be recorded.
REPORT OF CASES
A 54-year-old white man, a government purchasing agent, was admitted to the United States Naval Hospital,
Shields WE, Adamson NE, MacGregor JB. PEPTIC ULCER PERFORATION FOLLOWING ADMINISTRATION OF PHENYLBUTAZONE. JAMA. 1953;152(1):28–30. doi:10.1001/jama.1953.63690010004007d
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: